The research was presented at the meeting of the American Association for the Study of Liver Diseases in Boston and indicated that a combination of Gilead’s experimental drugs, sofosbuvir and daclatasvir cleared the hepatitis C virus in all 25 patients in a 12 week trial.
The biopharmaceutical company is in competition with a number of drugmakers to develop the next generation of Hepatitis C drugs including Abbott, Vertex and Merck. However, these results have given Gilead the competitive edge in this area of drug development, as explained by Micheal Yee, an RBC Capital Markets analyst, “Gilead will likely be the first to market with a simple and efficacious one pill, once-daily regimen. All this adds up so far to supporting our thesis that Gilead has a $5 billion plus drug.” Gilead have recently commenced the first Phase III trial.
Hepatitis C affects approximately 170 million people worldwide according to the World Health Organisation. The liver disease is traditionally treated using injection drugs but this treatment can cause unpleasant flu like symptoms. The new drugs in development by Gilead are taken as pills, have fewer side effects and shorter treatment durations.
Are you looking for a new position in the pharmaceutical industry?